Editor’s pick: Bioptimus
Start here
Bioptimus is featured in Nature Biotechnology's annual editor's pick. The company is developing multimodal, multiscale AI pathology models for biomarker identification and drug treatment prediction. Each year the journal highlights companies that received sizeable early-stage funding in the previous year.
Excerpted from Nature
Coverage timeline
Follow the coverage to see the different angles.
- NatureEditor’s pick: Bioptimus
Bioptimus is featured in Nature Biotechnology's annual editor's pick. The company is developing multimodal, multiscale AI pathology models for biomarker identification and drug treatment prediction. Each year the journal highlights companies that received sizeable early-stage funding in the previous year.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 19 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.